# The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

> **NCT01627314** · PHASE2 · TERMINATED · sponsor: **Fate Therapeutics** · enrollment: 62 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** ProHema-CB
- **BIOLOGICAL:** Untreated CB

## Key facts

- **NCT ID:** NCT01627314
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2016-03
- **Final completion:** 2017-05
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627314, "The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01627314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*